<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603980</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-002-102</org_study_id>
    <secondary_id>22 January 2008</secondary_id>
    <nct_id>NCT00603980</nct_id>
  </id_info>
  <brief_title>Staccato Alprazolam Abuse Liability</brief_title>
  <official_title>Abuse Liability Study of StaccatoÂ® Alprazolam for Inhalation in Subjects With Histories of Sedative Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and
      Staccato Placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 1 clinical study compared the abuse liabilities of Staccato Alprazolam, oral
      immediate-release alprazolam, and Staccato Placebo in 14 subjects with a history of sedative
      abuse. Subjects who met the inclusion/exclusion criteria received 2 mg of oral alprazolam and
      matching placebo over 2 sessions. Those who demonstrated greater liking for alprazolam versus
      placebo were eligible to participate in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The crossover schedule is planned according to a 7-treatment, 7-period Latin Square design due to E.J. Williams (1949), which is balanced for first-order carryover effects (Fleiss, 1986). Each subject will receive all treatments in this 7-treatment, 7- period Williams Square crossover design as suggested by Chen &amp; Tsong (2007). This Williams Square will include one replication by 1 subject of each of the 14 sequences</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>In order to reduce discrimination between placebo and active Staccato Alprazolam, taste blinding will be accomplished using a rapidly dissolving, intensely flavored product (candy, strip or breath spray). The product will be administered immediately after each oral capsule dosing (at the -60-min and 0- min time points).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Response to EDQ Question Number 5, &quot;Rate the Degree to Which You Would Like to Take the Drug Again&quot;</measure>
    <time_frame>End of day for each of the 7 crossover treatments</time_frame>
    <description>The End of Day Questionnaire (EDQ) is a 7-question computerized instrument in which subjects rate the overall effect of the drug they received that day. The primary outcome measure for this trial is the categorical response to question number 5, &quot;Rate the degree to which you would like to take the drug again&quot;, with a numerical value assigned to each of the responses allowed: 0=Not at all, 1=A little, 2=Moderately, 3=Quite a bit, 4=Very much</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EDQ Question Number 2 &quot;Rate Your Overall Liking of the Drug Effect&quot;</measure>
    <time_frame>End of day for each of the 7 crossover treatments</time_frame>
    <description>The within patient rank (1-7) of End of Day question number 2 (of primary interest), &quot;Rate your overall liking of the drug effect&quot;, response options range from -4 to +4:
4=Dislike very much
3=Dislike quite a bit
2=Dislike somewhat
1=Dislike, but not very much 0=NEUTRAL OR NO EFFECT
1=Like, but not very much
2=Like somewhat
3=Like quite a bit
4=Like very much Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDQ Question Number 6 &quot; Estimate the Amount of Money You Think the Drug You Took Today Would be Worth on the Street&quot;.</measure>
    <time_frame>End of day for each of the 7 crossover treatments</time_frame>
    <description>EDQ question number 6 (of primary interest),&quot; Estimate the amount of money you think the drug you took today would be worth on the street&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDQ Question Number 1, &quot;Rate the Overall Strength of the Drug Effect&quot;</measure>
    <time_frame>End of day for each of the 7 crossover treatments</time_frame>
    <description>The within patient rank (1-7) of End of Day question number 1, &quot;Rate the overall strength of the drug effect&quot;, response options range from 0-4:
0=No drug effect at all
Possible mild effect, but not sure
Definite mild effect
Moderate strong drug effect
Very strong drug effect Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDQ Question Number 7,&quot;What Would You be Willing to Pay for Today's Drug?&quot;</measure>
    <time_frame>End of day for each of the 7 crossover treatments</time_frame>
    <description>EDQ question number 7,&quot; What would you be willing to pay for today's drug?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum of DEQ Question 1 &quot;Rate the Strength of the Drug Effect&quot; (at the 10 Time Points, Predose Through 9 Hours)</measure>
    <time_frame>DEQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of Drug Effect Questionnaire question number 1: Rate the STRENGTH of the drug effect you are feeling RIGHT NOW; response options range for 0 to 4:
&quot;No drug effect at all&quot;=0, &quot;Possible mild effect, but not sure&quot;=1, &quot;Definite mild effect&quot;=2, &quot;Moderate strong drug effect&quot;=3, &quot;Very strong drug effect&quot;=4 Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum of DEQ Question 2 &quot;Rate Your Liking of the Drug Effect&quot; at the 10 Time Points (Predose Through 9 Hours)</measure>
    <time_frame>DEQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of maximum of the Rate your LIKING of the drug effect you are feeling RIGHT NOW; response options range from -4 to +4:
&quot;Dislike very much&quot;=-4, &quot;Dislike quite a bit&quot;=-3, &quot;Dislike somewhat&quot;=-2, &quot;Dislike, but not very much&quot;=-1, &quot;NEUTRAL OR NO EFFECT&quot;=0, &quot;Like, but not very much&quot;=1, &quot;Like somewhat&quot;=2, &quot;Like quite a bit&quot;=3, &quot;Like very much&quot;=4 Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer Rated Questionnaire 1) Maximum of Sedation/Sleepiness</measure>
    <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of Maximum of Observer Rated Questionnaire (ORQ): A trained and blinded staff member completed observer ratings as the subject completed the questionnaires and psychomotor assessment testing at each time point.
The observer rated the subject on sedation/sleepiness, muscle relaxation, impaired posture, impaired speech, confusion/disorientation, stimulation/arousal and strength of drug effect on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer Rated Questionnaire 2) Maximum of Muscle Relaxation Locomotor</measure>
    <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer Rated Questionnaire 3) Maximum of Muscle Relaxation Non-locomotor</measure>
    <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (non-locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer Rated Questionnaire 4) Maximum of Muscle Relaxation Posture</measure>
    <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (posture) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer Rated Questionnaire 5) Maximum of Speech</measure>
    <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of maximum of the observer rated the subject on speech on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer Rated Questionnaire 6) Maximum of Confusion/Disorientation</measure>
    <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of maximum of the observer rated the subject on Confusion/Disorientation on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer Rated Questionnaire 7) Maximum of Stimulation/Arousal</measure>
    <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of maximum of the observer rated the subject on Stimulation/Arousal on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observer Rated Questionnaire 8) Maximum of Drug Strength</measure>
    <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
    <description>The within patient rank (1-7) of maximum of the observer rated the subject on Drug Strength on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Abuse Liability of Staccato Alprazolam</condition>
  <arm_group>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 1: Q, 1, 2, 7, 3, 6, 4, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence Q, 2: 2, 3, 1, 4, 7, 5, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 3: Q, 3, 4, 2, 5, 1, 6, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 4: Q, 4, 5, 3, 6, 2, 7, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 5: Q, 5, 6, 4, 7, 3, 1, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 6: Q, 6, 7, 5, 1, 4, 2, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 7: Q, 7, 1, 6, 2, 5, 3, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 8: Q, 5, 4, 6, 3, 7, 2, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 9</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 9: Q, 6, 5, 7, 4, 1, 3, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 10: Q, 7, 6, 1, 5, 2, 4, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 11: Q, 1, 7, 2, 6, 3, 5, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 12: Q, 2, 1, 3, 7, 4, 6, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 13: Q, 3, 2, 4, 1, 5, 7, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence 14: Q, 4, 3, 5, 2, 6, 1, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled placebo + oral placebo</intervention_name>
    <description>Inhaled Staccato placebo + oral placebo</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_label>Treatment sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled alprazolam 0.5 mg</intervention_name>
    <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_label>Treatment sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled alprazolam 1 mg</intervention_name>
    <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_label>Treatment sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled alprazolam 2 mg</intervention_name>
    <description>Inhaled Staccato alprazolam 2 mg + oral placebo</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_label>Treatment sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral alprazolam 1 mg</intervention_name>
    <description>Oral alprazolam 1 mg + Inhaled placebo</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_label>Treatment sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral alprazolam 2 mg</intervention_name>
    <description>Oral alprazolam 2 mg + Inhaled placebo</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_label>Treatment sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral alprazolam 4 m</intervention_name>
    <description>Oral alprazolam 4 mg + Inhaled placebo</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_label>Treatment sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral alprazolam 2 mg qualifying session</intervention_name>
    <description>Qualifying session (2 mg oral alprazolam)</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_label>Treatment sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo qualifying session</intervention_name>
    <description>Qualifying control session (oral placebo)</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 10</arm_group_label>
    <arm_group_label>Treatment sequence 11</arm_group_label>
    <arm_group_label>Treatment sequence 12</arm_group_label>
    <arm_group_label>Treatment sequence 13</arm_group_label>
    <arm_group_label>Treatment sequence 14</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_label>Treatment sequence 7</arm_group_label>
    <arm_group_label>Treatment sequence 8</arm_group_label>
    <arm_group_label>Treatment sequence 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects between the ages of 18 to 55 years, inclusive, who have a
             history of substance abuse or dependence on barbiturates and/or benzodiazepine
             receptor agonists for their intoxicating effects

        Exclusion Criteria:

          -  Subjects with a significant current psychiatric illness or taking any psychotropic
             prescription medications for therapeutic uses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland R Griffiths, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Reissig CJ, Harrison JA, Carter LP, Griffiths RR. Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology (Berl). 2015 Mar;232(5):871-83. doi: 10.1007/s00213-014-3721-0. Epub 2014 Sep 9.</citation>
    <PMID>25199955</PMID>
  </results_reference>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <results_first_submitted>March 12, 2017</results_first_submitted>
  <results_first_submitted_qc>December 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>December 29, 2019</last_update_submitted>
  <last_update_submitted_qc>December 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Each participants was to receive all 7 interventions in a randomized order in a crossover design</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects Entering</title>
          <description>All subjects entering the crossover qualification period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Qualification</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inconsistent data reporting</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Main Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>14th subject completed trial</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Qualifying Session (Includes Crossover Group)</title>
          <description>All subjects received Placebo and Oral alprazolam 2 mg in a randomized order to Qualify
Each subject was to receive all 7 interventions (Placebo, Oral alprazolam 1, 2 &amp; 3 mg, Inhaled alprazolam 0.5, 1, &amp; 2 mg) in a randomized order in a crossover design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.032" spread="38.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response to EDQ Question Number 5, &quot;Rate the Degree to Which You Would Like to Take the Drug Again&quot;</title>
        <description>The End of Day Questionnaire (EDQ) is a 7-question computerized instrument in which subjects rate the overall effect of the drug they received that day. The primary outcome measure for this trial is the categorical response to question number 5, &quot;Rate the degree to which you would like to take the drug again&quot;, with a numerical value assigned to each of the responses allowed: 0=Not at all, 1=A little, 2=Moderately, 3=Quite a bit, 4=Very much</description>
        <time_frame>End of day for each of the 7 crossover treatments</time_frame>
        <population>Efficacy (crossover) Population, n=14. LSM &amp; SEM are based on all 14 subjects completing all 7 treatments. PROC MIXED model used assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Response to EDQ Question Number 5, &quot;Rate the Degree to Which You Would Like to Take the Drug Again&quot;</title>
          <description>The End of Day Questionnaire (EDQ) is a 7-question computerized instrument in which subjects rate the overall effect of the drug they received that day. The primary outcome measure for this trial is the categorical response to question number 5, &quot;Rate the degree to which you would like to take the drug again&quot;, with a numerical value assigned to each of the responses allowed: 0=Not at all, 1=A little, 2=Moderately, 3=Quite a bit, 4=Very much</description>
          <population>Efficacy (crossover) Population, n=14. LSM &amp; SEM are based on all 14 subjects completing all 7 treatments. PROC MIXED model used assigns the same SEM to all 7 treatments.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.349"/>
                    <measurement group_id="O2" value="1.714" spread="0.349"/>
                    <measurement group_id="O3" value="2.143" spread="0.349"/>
                    <measurement group_id="O4" value="2.286" spread="0.349"/>
                    <measurement group_id="O5" value="1.00" spread="0.349"/>
                    <measurement group_id="O6" value="1.714" spread="0.349"/>
                    <measurement group_id="O7" value="2.214" spread="0.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EDQ Question Number 2 &quot;Rate Your Overall Liking of the Drug Effect&quot;</title>
        <description>The within patient rank (1-7) of End of Day question number 2 (of primary interest), &quot;Rate your overall liking of the drug effect&quot;, response options range from -4 to +4:
4=Dislike very much
3=Dislike quite a bit
2=Dislike somewhat
1=Dislike, but not very much 0=NEUTRAL OR NO EFFECT
1=Like, but not very much
2=Like somewhat
3=Like quite a bit
4=Like very much Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>End of day for each of the 7 crossover treatments</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>EDQ Question Number 2 &quot;Rate Your Overall Liking of the Drug Effect&quot;</title>
          <description>The within patient rank (1-7) of End of Day question number 2 (of primary interest), &quot;Rate your overall liking of the drug effect&quot;, response options range from -4 to +4:
4=Dislike very much
3=Dislike quite a bit
2=Dislike somewhat
1=Dislike, but not very much 0=NEUTRAL OR NO EFFECT
1=Like, but not very much
2=Like somewhat
3=Like quite a bit
4=Like very much Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.679" spread="0.349"/>
                    <measurement group_id="O2" value="4.214" spread="0.349"/>
                    <measurement group_id="O3" value="4.429" spread="0.349"/>
                    <measurement group_id="O4" value="4.607" spread="0.349"/>
                    <measurement group_id="O5" value="2.571" spread="0.349"/>
                    <measurement group_id="O6" value="4.857" spread="0.349"/>
                    <measurement group_id="O7" value="5.643" spread="0.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EDQ Question Number 6 &quot; Estimate the Amount of Money You Think the Drug You Took Today Would be Worth on the Street&quot;.</title>
        <description>EDQ question number 6 (of primary interest),&quot; Estimate the amount of money you think the drug you took today would be worth on the street&quot;.</description>
        <time_frame>End of day for each of the 7 crossover treatments</time_frame>
        <population>Efficacy (crossover) Population, n=14. LSM &amp; SEM are based on all 14 subjects completing all 7 treatments. PROC MIXED model used assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>EDQ Question Number 6 &quot; Estimate the Amount of Money You Think the Drug You Took Today Would be Worth on the Street&quot;.</title>
          <description>EDQ question number 6 (of primary interest),&quot; Estimate the amount of money you think the drug you took today would be worth on the street&quot;.</description>
          <population>Efficacy (crossover) Population, n=14. LSM &amp; SEM are based on all 14 subjects completing all 7 treatments. PROC MIXED model used assigns the same SEM to all 7 treatments.</population>
          <units>Dollars ($)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" spread="0.402"/>
                    <measurement group_id="O2" value="3.571" spread="0.402"/>
                    <measurement group_id="O3" value="7.071" spread="0.402"/>
                    <measurement group_id="O4" value="8.714" spread="0.402"/>
                    <measurement group_id="O5" value="2.857" spread="0.402"/>
                    <measurement group_id="O6" value="4.286" spread="0.402"/>
                    <measurement group_id="O7" value="8.571" spread="0.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EDQ Question Number 1, &quot;Rate the Overall Strength of the Drug Effect&quot;</title>
        <description>The within patient rank (1-7) of End of Day question number 1, &quot;Rate the overall strength of the drug effect&quot;, response options range from 0-4:
0=No drug effect at all
Possible mild effect, but not sure
Definite mild effect
Moderate strong drug effect
Very strong drug effect Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>End of day for each of the 7 crossover treatments</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>EDQ Question Number 1, &quot;Rate the Overall Strength of the Drug Effect&quot;</title>
          <description>The within patient rank (1-7) of End of Day question number 1, &quot;Rate the overall strength of the drug effect&quot;, response options range from 0-4:
0=No drug effect at all
Possible mild effect, but not sure
Definite mild effect
Moderate strong drug effect
Very strong drug effect Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.429" spread="0.317"/>
                    <measurement group_id="O2" value="3.536" spread="0.317"/>
                    <measurement group_id="O3" value="4.821" spread="0.317"/>
                    <measurement group_id="O4" value="5.429" spread="0.317"/>
                    <measurement group_id="O5" value="2.893" spread="0.317"/>
                    <measurement group_id="O6" value="4.143" spread="0.317"/>
                    <measurement group_id="O7" value="5.750" spread="0.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EDQ Question Number 7,&quot;What Would You be Willing to Pay for Today's Drug?&quot;</title>
        <description>EDQ question number 7,&quot; What would you be willing to pay for today's drug?&quot;</description>
        <time_frame>End of day for each of the 7 crossover treatments</time_frame>
        <population>Efficacy (crossover) Population, n=14. LSM &amp; SEM are based on all 14 subjects completing all 7 treatments. PROC MIXED model used assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>EDQ Question Number 7,&quot;What Would You be Willing to Pay for Today's Drug?&quot;</title>
          <description>EDQ question number 7,&quot; What would you be willing to pay for today's drug?&quot;</description>
          <population>Efficacy (crossover) Population, n=14. LSM &amp; SEM are based on all 14 subjects completing all 7 treatments. PROC MIXED model used assigns the same SEM to all 7 treatments.</population>
          <units>Dollars ($)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.607" spread="0.387"/>
                    <measurement group_id="O2" value="3.821" spread="0.387"/>
                    <measurement group_id="O3" value="4.571" spread="0.387"/>
                    <measurement group_id="O4" value="5.179" spread="0.387"/>
                    <measurement group_id="O5" value="2.964" spread="0.387"/>
                    <measurement group_id="O6" value="4.107" spread="0.387"/>
                    <measurement group_id="O7" value="5.750" spread="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum of DEQ Question 1 &quot;Rate the Strength of the Drug Effect&quot; (at the 10 Time Points, Predose Through 9 Hours)</title>
        <description>The within patient rank (1-7) of Drug Effect Questionnaire question number 1: Rate the STRENGTH of the drug effect you are feeling RIGHT NOW; response options range for 0 to 4:
&quot;No drug effect at all&quot;=0, &quot;Possible mild effect, but not sure&quot;=1, &quot;Definite mild effect&quot;=2, &quot;Moderate strong drug effect&quot;=3, &quot;Very strong drug effect&quot;=4 Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>DEQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum of DEQ Question 1 &quot;Rate the Strength of the Drug Effect&quot; (at the 10 Time Points, Predose Through 9 Hours)</title>
          <description>The within patient rank (1-7) of Drug Effect Questionnaire question number 1: Rate the STRENGTH of the drug effect you are feeling RIGHT NOW; response options range for 0 to 4:
&quot;No drug effect at all&quot;=0, &quot;Possible mild effect, but not sure&quot;=1, &quot;Definite mild effect&quot;=2, &quot;Moderate strong drug effect&quot;=3, &quot;Very strong drug effect&quot;=4 Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.571" spread="0.340"/>
                    <measurement group_id="O2" value="3.143" spread="0.340"/>
                    <measurement group_id="O3" value="4.714" spread="0.340"/>
                    <measurement group_id="O4" value="5.536" spread="0.340"/>
                    <measurement group_id="O5" value="3.036" spread="0.340"/>
                    <measurement group_id="O6" value="4.250" spread="0.340"/>
                    <measurement group_id="O7" value="5.750" spread="0.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum of DEQ Question 2 &quot;Rate Your Liking of the Drug Effect&quot; at the 10 Time Points (Predose Through 9 Hours)</title>
        <description>The within patient rank (1-7) of maximum of the Rate your LIKING of the drug effect you are feeling RIGHT NOW; response options range from -4 to +4:
&quot;Dislike very much&quot;=-4, &quot;Dislike quite a bit&quot;=-3, &quot;Dislike somewhat&quot;=-2, &quot;Dislike, but not very much&quot;=-1, &quot;NEUTRAL OR NO EFFECT&quot;=0, &quot;Like, but not very much&quot;=1, &quot;Like somewhat&quot;=2, &quot;Like quite a bit&quot;=3, &quot;Like very much&quot;=4 Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>DEQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum of DEQ Question 2 &quot;Rate Your Liking of the Drug Effect&quot; at the 10 Time Points (Predose Through 9 Hours)</title>
          <description>The within patient rank (1-7) of maximum of the Rate your LIKING of the drug effect you are feeling RIGHT NOW; response options range from -4 to +4:
&quot;Dislike very much&quot;=-4, &quot;Dislike quite a bit&quot;=-3, &quot;Dislike somewhat&quot;=-2, &quot;Dislike, but not very much&quot;=-1, &quot;NEUTRAL OR NO EFFECT&quot;=0, &quot;Like, but not very much&quot;=1, &quot;Like somewhat&quot;=2, &quot;Like quite a bit&quot;=3, &quot;Like very much&quot;=4 Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.607" spread="0.343"/>
                    <measurement group_id="O2" value="3.500" spread="0.343"/>
                    <measurement group_id="O3" value="4.536" spread="0.343"/>
                    <measurement group_id="O4" value="5.536" spread="0.343"/>
                    <measurement group_id="O5" value="2.893" spread="0.343"/>
                    <measurement group_id="O6" value="4.250" spread="0.343"/>
                    <measurement group_id="O7" value="5.679" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observer Rated Questionnaire 1) Maximum of Sedation/Sleepiness</title>
        <description>The within patient rank (1-7) of Maximum of Observer Rated Questionnaire (ORQ): A trained and blinded staff member completed observer ratings as the subject completed the questionnaires and psychomotor assessment testing at each time point.
The observer rated the subject on sedation/sleepiness, muscle relaxation, impaired posture, impaired speech, confusion/disorientation, stimulation/arousal and strength of drug effect on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Observer Rated Questionnaire 1) Maximum of Sedation/Sleepiness</title>
          <description>The within patient rank (1-7) of Maximum of Observer Rated Questionnaire (ORQ): A trained and blinded staff member completed observer ratings as the subject completed the questionnaires and psychomotor assessment testing at each time point.
The observer rated the subject on sedation/sleepiness, muscle relaxation, impaired posture, impaired speech, confusion/disorientation, stimulation/arousal and strength of drug effect on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.250" spread="0.313"/>
                    <measurement group_id="O2" value="3.679" spread="0.313"/>
                    <measurement group_id="O3" value="4.607" spread="0.313"/>
                    <measurement group_id="O4" value="4.714" spread="0.313"/>
                    <measurement group_id="O5" value="3.929" spread="0.313"/>
                    <measurement group_id="O6" value="4.000" spread="0.313"/>
                    <measurement group_id="O7" value="4.821" spread="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observer Rated Questionnaire 2) Maximum of Muscle Relaxation Locomotor</title>
        <description>The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Observer Rated Questionnaire 2) Maximum of Muscle Relaxation Locomotor</title>
          <description>The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Maximum of the 10 time points (predose through 9 hours) Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.464" spread="0.287"/>
                    <measurement group_id="O2" value="2.964" spread="0.287"/>
                    <measurement group_id="O3" value="4.643" spread="0.287"/>
                    <measurement group_id="O4" value="6.357" spread="0.287"/>
                    <measurement group_id="O5" value="2.821" spread="0.287"/>
                    <measurement group_id="O6" value="3.571" spread="0.287"/>
                    <measurement group_id="O7" value="5.179" spread="0.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observer Rated Questionnaire 3) Maximum of Muscle Relaxation Non-locomotor</title>
        <description>The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (non-locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Observer Rated Questionnaire 3) Maximum of Muscle Relaxation Non-locomotor</title>
          <description>The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (non-locomotor) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.536" spread="0.282"/>
                    <measurement group_id="O2" value="3.036" spread="0.282"/>
                    <measurement group_id="O3" value="4.607" spread="0.282"/>
                    <measurement group_id="O4" value="6.393" spread="0.282"/>
                    <measurement group_id="O5" value="2.714" spread="0.282"/>
                    <measurement group_id="O6" value="3.786" spread="0.282"/>
                    <measurement group_id="O7" value="4.929" spread="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observer Rated Questionnaire 4) Maximum of Muscle Relaxation Posture</title>
        <description>The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (posture) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Observer Rated Questionnaire 4) Maximum of Muscle Relaxation Posture</title>
          <description>The within patient rank (1-7) of maximum of the observer rated the subject on muscle relaxation (posture) on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.750" spread="0.337"/>
                    <measurement group_id="O2" value="2.893" spread="0.337"/>
                    <measurement group_id="O3" value="3.964" spread="0.337"/>
                    <measurement group_id="O4" value="6.250" spread="0.337"/>
                    <measurement group_id="O5" value="2.929" spread="0.337"/>
                    <measurement group_id="O6" value="2.929" spread="0.337"/>
                    <measurement group_id="O7" value="2.929" spread="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observer Rated Questionnaire 5) Maximum of Speech</title>
        <description>The within patient rank (1-7) of maximum of the observer rated the subject on speech on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Observer Rated Questionnaire 5) Maximum of Speech</title>
          <description>The within patient rank (1-7) of maximum of the observer rated the subject on speech on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.214" spread="0.284"/>
                    <measurement group_id="O2" value="2.893" spread="0.284"/>
                    <measurement group_id="O3" value="4.786" spread="0.284"/>
                    <measurement group_id="O4" value="6.393" spread="0.284"/>
                    <measurement group_id="O5" value="3.071" spread="0.284"/>
                    <measurement group_id="O6" value="3.071" spread="0.284"/>
                    <measurement group_id="O7" value="5.357" spread="0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observer Rated Questionnaire 6) Maximum of Confusion/Disorientation</title>
        <description>The within patient rank (1-7) of maximum of the observer rated the subject on Confusion/Disorientation on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Observer Rated Questionnaire 6) Maximum of Confusion/Disorientation</title>
          <description>The within patient rank (1-7) of maximum of the observer rated the subject on Confusion/Disorientation on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.929" spread="0.282"/>
                    <measurement group_id="O2" value="2.821" spread="0.282"/>
                    <measurement group_id="O3" value="4.893" spread="0.282"/>
                    <measurement group_id="O4" value="6.429" spread="0.282"/>
                    <measurement group_id="O5" value="3.393" spread="0.282"/>
                    <measurement group_id="O6" value="3.107" spread="0.282"/>
                    <measurement group_id="O7" value="5.429" spread="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observer Rated Questionnaire 7) Maximum of Stimulation/Arousal</title>
        <description>The within patient rank (1-7) of maximum of the observer rated the subject on Stimulation/Arousal on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O2">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Observer Rated Questionnaire 7) Maximum of Stimulation/Arousal</title>
          <description>The within patient rank (1-7) of maximum of the observer rated the subject on Stimulation/Arousal on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.964" spread="0.087"/>
                    <measurement group_id="O2" value="3.964" spread="0.087"/>
                    <measurement group_id="O3" value="3.964" spread="0.087"/>
                    <measurement group_id="O4" value="3.964" spread="0.087"/>
                    <measurement group_id="O5" value="3.964" spread="0.087"/>
                    <measurement group_id="O6" value="3.964" spread="0.087"/>
                    <measurement group_id="O7" value="4,214" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observer Rated Questionnaire 8) Maximum of Drug Strength</title>
        <description>The within patient rank (1-7) of maximum of the observer rated the subject on Drug Strength on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
        <time_frame>ORQ was assessed at the 10 time points (predose through 9 hours)</time_frame>
        <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Alprazolam 1 mg</title>
            <description>Oral alprazolam 1 mg + inhaled placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inhaled Staccato Placebo +oral placebo</description>
          </group>
          <group group_id="O3">
            <title>Oral Alprazolam 2 mg</title>
            <description>Oral alprazolam 2 mg + inhaled placebo</description>
          </group>
          <group group_id="O4">
            <title>Oral Alprazolam 4 mg</title>
            <description>Oral alprazolam 4 mg + inhaled placebo</description>
          </group>
          <group group_id="O5">
            <title>Inhaled Alprazolam 0.5 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
          </group>
          <group group_id="O6">
            <title>Inhaled Alprazolam 1 mg</title>
            <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
          </group>
          <group group_id="O7">
            <title>Inhaled Alprazolam 2 mg</title>
            <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Observer Rated Questionnaire 8) Maximum of Drug Strength</title>
          <description>The within patient rank (1-7) of maximum of the observer rated the subject on Drug Strength on a five-point scale from 0 (indicating normal or no effect) to 4 (indicating extreme drug effect).
Thus a higher rank means a stronger drug effect and a lower rank a lesser drug effect</description>
          <population>Efficacy (crossover) Population, n=14
LS Means via SAS PROC MIXED non-parametric model (ranks within subject), treatment and period as fixed effects, ddf=72
LSM &amp; SEM are based on the ranks of scores within each subject across all 14 subjects completing all 7 treatments.
PROC MIXED model assigns the same SEM to all 7 treatments.</population>
          <units>Rank across the 7 treatments</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.786" spread="0.286"/>
                    <measurement group_id="O2" value="1.714" spread="0.286"/>
                    <measurement group_id="O3" value="4.571" spread="0.286"/>
                    <measurement group_id="O4" value="6.321" spread="0.286"/>
                    <measurement group_id="O5" value="3.000" spread="0.286"/>
                    <measurement group_id="O6" value="3.929" spread="0.286"/>
                    <measurement group_id="O7" value="5.679" spread="0.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment</time_frame>
      <desc>Adverse events (AEs) were assessed at 14 pre-specified time points for the 24-hour period after dosing, as well as whenever spontaneously reported by the subjects or study staff</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Inhaled Staccato Placebo +oral placebo</description>
        </group>
        <group group_id="E2">
          <title>Oral Alprazolam 1 mg</title>
          <description>Oral alprazolam 1 mg + inhaled placebo</description>
        </group>
        <group group_id="E3">
          <title>Oral Alprazolam 2 mg</title>
          <description>Oral alprazolam 2 mg + inhaled placebo</description>
        </group>
        <group group_id="E4">
          <title>Oral Alprazolam 4 mg</title>
          <description>Oral alprazolam 4 mg + inhaled placebo</description>
        </group>
        <group group_id="E5">
          <title>Inhaled Alprazolam 0.5 mg</title>
          <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo</description>
        </group>
        <group group_id="E6">
          <title>Inhaled Alprazolam 1 mg</title>
          <description>Inhaled Staccato alprazolam 1 mg + oral placebo</description>
        </group>
        <group group_id="E7">
          <title>Inhaled Alprazolam 2 mg</title>
          <description>Inhaled Staccato alprazolam 0.5 mg + oral placebo placebo</description>
        </group>
        <group group_id="E8">
          <title>Qualifying Session 2 mg Oral</title>
          <description>Qualifying session, 2 mg oral alprazolam</description>
        </group>
        <group group_id="E9">
          <title>Qualifying Session Oral Placebo</title>
          <description>Qualifying session, oral placebo (alprazolam 0 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation of the current study was the lack of assessment of drug plasma levels. The differences in abuse potential measures may be due to differences in absorption, peak drug plasma levels, or other PK parameters</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Executive VP, Research &amp; Development, Regulatory &amp; Quality</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7071</phone>
      <email>ClinicalTrialsInfo@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

